These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19574635)

  • 1. Structure of the lamin A/C R482W mutant responsible for dominant familial partial lipodystrophy (FPLD).
    Magracheva E; Kozlov S; Stewart CL; Wlodawer A; Zdanov A
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2009 Jul; 65(Pt 7):665-70. PubMed ID: 19574635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico investigation of molecular mechanism of laminopathy caused by a point mutation (R482W) in lamin A/C protein.
    Rajendran V; Purohit R; Sethumadhavan R
    Amino Acids; 2012 Aug; 43(2):603-15. PubMed ID: 21989830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C.
    Speckman RA; Garg A; Du F; Bennett L; Veile R; Arioglu E; Taylor SI; Lovett M; Bowcock AM
    Am J Hum Genet; 2000 Apr; 66(4):1192-8. PubMed ID: 10739751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulation of Fragile X-related protein 1 by the lipodystrophic lamin A p.R482W mutation elicits a myogenic gene expression program in preadipocytes.
    Oldenburg AR; Delbarre E; Thiede B; Vigouroux C; Collas P
    Hum Mol Genet; 2014 Mar; 23(5):1151-62. PubMed ID: 24108105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The p.R482W substitution in A-type lamins deregulates SREBP1 activity in Dunnigan-type familial partial lipodystrophy.
    Vadrot N; Duband-Goulet I; Cabet E; Attanda W; Barateau A; Vicart P; Gerbal F; Briand N; Vigouroux C; Oldenburg AR; Lund EG; Collas P; Buendia B
    Hum Mol Genet; 2015 Apr; 24(7):2096-109. PubMed ID: 25524705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The R439C mutation in LMNA causes lamin oligomerization and susceptibility to oxidative stress.
    Verstraeten VL; Caputo S; van Steensel MA; Duband-Goulet I; Zinn-Justin S; Kamps M; Kuijpers HJ; Ostlund C; Worman HJ; Briedé JJ; Le Dour C; Marcelis CL; van Geel M; Steijlen PM; van den Wijngaard A; Ramaekers FC; Broers JL
    J Cell Mol Med; 2009 May; 13(5):959-71. PubMed ID: 19220582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A/C mutations.
    Subramanyam L; Simha V; Garg A
    Clin Genet; 2010 Jul; 78(1):66-73. PubMed ID: 20041886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies specific for disease-associated point-mutants: lamin A/C R453W and R482W.
    Roblek M; Schüchner S; Huber V; Ollram K; Vlcek-Vesely S; Foisner R; Wehnert M; Ogris E
    PLoS One; 2010 May; 5(5):e10604. PubMed ID: 20498701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LMNA missense mutations causing familial partial lipodystrophy do not lead to an accumulation of prelamin A.
    Tu Y; Sánchez-Iglesias S; Araújo-Vilar D; Fong LG; Young SG
    Nucleus; 2016 Sep; 7(5):512-521. PubMed ID: 27841971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial partial lipodystrophy due to the LMNA R482W mutation with multinodular goitre, extrapyramidal syndrome and primary hyperaldosteronism.
    Vantyghem MC; Faivre-Defrance F; Marcelli-Tourvieille S; Fermon C; Evrard A; Bourdelle-Hego MF; Vigouroux C; Defebvre L; Delemer B; Wemeau JL
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):247-9. PubMed ID: 17524034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lipodystrophic hotspot lamin A p.R482W mutation deregulates the mesodermal inducer T/Brachyury and early vascular differentiation gene networks.
    Briand N; Guénantin AC; Jeziorowska D; Shah A; Mantecon M; Capel E; Garcia M; Oldenburg A; Paulsen J; Hulot JS; Vigouroux C; Collas P
    Hum Mol Genet; 2018 Apr; 27(8):1447-1459. PubMed ID: 29438482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy.
    Vigouroux C; Magré J; Vantyghem MC; Bourut C; Lascols O; Shackleton S; Lloyd DJ; Guerci B; Padova G; Valensi P; Grimaldi A; Piquemal R; Touraine P; Trembath RC; Capeau J
    Diabetes; 2000 Nov; 49(11):1958-62. PubMed ID: 11078466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of nuclear lamin A mutations in Dunnigan-type familial partial lipodystrophy.
    Hegele RA; Cao H; Anderson CM; Hramiak IM
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3431-5. PubMed ID: 10999845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamin A tail modification by SUMO1 is disrupted by familial partial lipodystrophy-causing mutations.
    Simon DN; Domaradzki T; Hofmann WA; Wilson KL
    Mol Biol Cell; 2013 Feb; 24(3):342-50. PubMed ID: 23243001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural instability of lamin A tail domain modulates its assembly and higher order function in Emery-Dreifuss muscular dystrophy.
    Mio M; Sugiki T; Matsuda C; Mitsuhashi H; Kojima C; Chan SY; Hayashi YK; Mio K
    Biochem Biophys Res Commun; 2019 Apr; 512(1):22-28. PubMed ID: 30853177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities.
    Vantyghem MC; Pigny P; Maurage CA; Rouaix-Emery N; Stojkovic T; Cuisset JM; Millaire A; Lascols O; Vermersch P; Wemeau JL; Capeau J; Vigouroux C
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5337-46. PubMed ID: 15531479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a/c gene.
    Garg A; Vinaitheerthan M; Weatherall PT; Bowcock AM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):59-65. PubMed ID: 11231979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy.
    Araújo-Vilar D; Lado-Abeal J; Palos-Paz F; Lattanzi G; Bandín MA; Bellido D; Domínguez-Gerpe L; Calvo C; Pérez O; Ramazanova A; Martínez-Sánchez N; Victoria B; Costa-Freitas AT
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):61-8. PubMed ID: 18031308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cosegregation of focal segmental glomerulosclerosis in a family with familial partial lipodystrophy due to a mutation in LMNA.
    Thong KM; Xu Y; Cook J; Takou A; Wagner B; Kawar B; Ong AC
    Nephron Clin Pract; 2013; 124(1-2):31-7. PubMed ID: 24080738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance.
    Boschmann M; Engeli S; Moro C; Luedtke A; Adams F; Gorzelniak K; Rahn G; Mähler A; Dobberstein K; Krüger A; Schmidt S; Spuler S; Luft FC; Smith SR; Schmidt HH; Jordan J
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1634-43. PubMed ID: 20130076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.